BridgeMD
New treatment option for Acute Bronchiolitis
Official title High Flow Nasal Cannula Weaning in Acute Bronchiolitis
ClinicalTrials.gov ID: NCT06321133
What this study is testing
- What it's testing
- The goal of this clinical study is to compared two different strategies to end high flow nasal cannula treatment in acute bronchiolitis. This study compared the immediate ending of high flow treatment to weaning strategy, in which the flow rate is gradually decreased.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 0 to 12
You may be able to join if
- Clinically diagnosed acute bronchiolitis
- High flow nasal cannula treatment has lasted for at least 12 hours
- Measured saturation 95 or more with room air
- High flow rate is maximum 2l/kg/min
- The treating doctors considers the infant suitable to be without high flow
You likely can't join if
- Major congenital anomaly of lungs, hearts or diaphragm
- Bacterial pneumonia
- Parents do not give consent
The study team makes the final eligibility decision.
Where it's taking place
- Joensuu, Finland
- Jyväskylä, Finland
- Kuopio, Finland
- Mikkeli, Finland
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0 months to 12 months. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Joensuu, Finland; Jyväskylä, Finland; Kuopio, Finland; Mikkeli, Finland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.